What Causes Alzheimer’s? 4 Leading Theories, Explained

TL;DR

Before you orderOffer from Amazon

Get health and wellness essentials delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

A Being Patient report describes four leading theories about Alzheimer’s: amyloid buildup, tau tangles, inflammation and vascular damage. The theories may explain different parts of the disease, but researchers have not established one complete cause; current evidence also supports treatments and tests aimed at some biological changes.

Researchers have not identified a single cause of Alzheimer’s disease, but four leading theories link its progression to amyloid plaques, tau tangles, inflammation and damage to blood vessels. A Being Patient report explains how each may contribute to neurons failing and dying, while emphasizing that the theories account for parts of the disease rather than a settled, complete explanation.

The theories begin with a shared observation: Alzheimer’s progressively damages neurons and the connections they use to pass signals. The disease often affects the hippocampus, which helps form new memories, before damage can spread to brain functions involved in language, judgment, behavior and coordination. Scientists continue to study what initiates that damage and how the different biological processes interact.

The amyloid hypothesis, long a dominant framework for Alzheimer’s research, holds that beta-amyloid fragments accumulate outside neurons and form plaques. Researchers propose that this buildup disrupts communication and may trigger other damage, including tau changes. Amyloid can be detected through PET imaging and spinal-fluid tests; in May 2025, the FDA cleared a blood test to aid in identifying amyloid pathology associated with Alzheimer’s, according to the report.

The tau theory focuses on abnormal changes to tau, a protein that helps stabilize structures inside neurons. When tau forms tangles, the cell’s internal transport system can be disrupted. The report also describes inflammation and vascular damage as leading areas of research: immune activity in the brain may contribute to injury, while problems affecting blood vessels can impair the delivery of oxygen and nutrients. These mechanisms may overlap rather than operate as competing, mutually exclusive explanations.

How Theories Shape Treatment

These theories matter because they guide both drug development and efforts to diagnose Alzheimer’s before symptoms become severe. Anti-amyloid medicines reflect the view that removing or reducing plaques can affect the course of disease. The report says the FDA-approved drugs lecanemab and donanemab modestly slowed cognitive decline in clinical trials among people in early stages of Alzheimer’s. They are not cures and carry risks, including brain swelling and bleeding, requiring regular monitoring.

The mixed record also shows why a biological marker is not the same as a full explanation or a treatment that restores lost abilities. Aducanumab, the first FDA-approved anti-amyloid drug, cleared plaques but had unconvincing evidence of clinical benefit; its maker discontinued it in 2024, the report says. Researchers are still testing whether targeting amyloid, tau or other processes can produce meaningful benefits for different patients.

For readers and families, the practical point is that Alzheimer’s is a progressive brain disease whose causes are still under investigation. New tests may help identify disease-related changes, but a positive marker does not by itself resolve which processes are driving a person’s symptoms or what treatment will help them. Medical decisions should be discussed with qualified health professionals.

From Plaques To Multiple Mechanisms

The disease is named for psychiatrist Alois Alzheimer, who described changes in the brain of Auguste Deter, a former patient, in 1906. He observed clumps between brain cells and twisted fibers within them, later known as amyloid plaques and tau tangles. Those findings remain hallmarks, but identifying them did not settle why they form or how they cause the full range of symptoms.

For decades, amyloid has been central to Alzheimer’s research and drug development. The report notes that amyloid accumulation may begin many years before symptoms, and that plaques can now be assessed using imaging and biological tests. Meanwhile, the report cites the Alzheimer’s Association’s 2026 Facts and Figures report, which estimates 7.4 million Americans aged 65 and older are living with Alzheimer’s dementia. That scale gives the search for causes direct relevance to patients, caregivers and health systems.

“Both γ-secretase and β-secretase inhibitors, which strongly inhibit amyloid-beta production, worsen cognitive and clinical performance in early and late stages of Alzheimer’s disease.”

— Bruno Imbimbo, a researcher at Chiesi Farmaceutici, speaking to Being Patient

What The Theories Cannot Explain

No single theory explains every feature of Alzheimer’s or establishes exactly what sets the disease in motion. The report presents amyloid, tau, inflammation and vascular damage as leading explanations, but does not show that one has been proven to be the sole cause. It remains uncertain how the processes influence one another, why some people develop symptoms while others with biological changes may not, and which patients benefit most from treatments targeting a particular process.

Evidence from amyloid-targeting medicines is mixed: some newer drugs modestly slowed decline in trials, while earlier efforts to block amyloid production raised concerns about worsening clinical performance, as Imbimbo noted. The findings do not establish that all amyloid-directed approaches have the same effect. Treatment benefits, risks and the significance of test results remain specific matters for research and clinical assessment.

Further Research And Clinical Evidence

Researchers will continue testing treatments that target amyloid and tau, as well as biological processes such as inflammation and vascular injury. Further clinical evidence is needed to clarify which mechanisms matter most at different stages, whether combining approaches can improve outcomes, and how best to balance potential benefit against treatment risks.

Blood tests and other biomarkers may also become more useful in identifying Alzheimer’s-related changes, but their role should be understood in line with what each test is cleared or validated to do. For patients and families, the next steps remain careful clinical evaluation and discussion with a qualified professional; for scientists, the central task is establishing how these disease processes connect and which interventions can meaningfully slow decline.

Key Questions

What are the four leading theories about Alzheimer’s?

The report describes theories involving amyloid plaques, tau tangles, inflammation in the brain and damage to blood vessels. They may overlap, and none is established as a complete explanation on its own.

Is amyloid proven to be the sole cause?

No. Amyloid has been central to Alzheimer’s research, and some approved drugs target it, but researchers continue to debate its role and how it relates to other processes. The evidence does not establish amyloid as the sole cause.

Do current Alzheimer’s medicines cure the disease?

No. The report says lecanemab and donanemab modestly slowed cognitive decline in trials among people in early stages of Alzheimer’s. They are not cures and can carry risks, including brain swelling and bleeding.

Can a blood test diagnose Alzheimer’s?

The report says the FDA cleared a blood test in May 2025 to aid in identifying amyloid pathology linked to Alzheimer’s. That description is narrower than saying a blood test alone gives a complete diagnosis; discuss testing and results with a qualified health professional.

Source: rss